USD
+$0.00
(+0.00%
)At Close (As of Sep 18, 2025)
$776.92M
Market Cap
-
P/E Ratio
-3.9
EPS
$19.18
52 Week High
$4.45
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $8.8M |
Total Revenue | $27M |
Cost Of Revenue | $18M |
Costof Goods And Services Sold | $18M |
Operating Income | -$184M |
Selling General And Administrative | $51M |
Research And Development | $144M |
Operating Expenses | $196M |
Investment Income Net | - |
Net Interest Income | -$42M |
Interest Income | $21M |
Interest Expense | $64M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $13M |
Income Before Tax | -$237M |
Income Tax Expense | $2.4M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$240M |
Comprehensive Income Net Of Tax | - |
Ebit | -$173M |
Ebitda | -$161M |
Net Income | -$240M |
Field | Value (USD) |
---|---|
Total Assets | $557M |
Total Current Assets | $390M |
Cash And Cash Equivalents At Carrying Value | $159M |
Cash And Short Term Investments | $159M |
Inventory | $0 |
Current Net Receivables | $5.9M |
Total Non Current Assets | $166M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $71M |
Intangible Assets Excluding Goodwill | $71M |
Goodwill | $22M |
Investments | - |
Long Term Investments | $27M |
Short Term Investments | $209M |
Other Current Assets | $17M |
Other Non Current Assets | - |
Total Liabilities | $563M |
Total Current Liabilities | $40M |
Current Accounts Payable | $7.2M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $7.2M |
Total Non Current Liabilities | $523M |
Capital Lease Obligations | $15M |
Long Term Debt | $51M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $66M |
Other Current Liabilities | $26M |
Other Non Current Liabilities | $454M |
Total Shareholder Equity | -$6.8M |
Treasury Stock | - |
Retained Earnings | -$1.1B |
Common Stock | $2.9M |
Common Stock Shares Outstanding | $49M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$183M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $13M |
Capital Expenditures | $3.4M |
Change In Receivables | - |
Change In Inventory | $2.4M |
Profit Loss | - |
Cashflow From Investment | $163M |
Cashflow From Financing | -$59M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$240M |
Field | Value (USD) |
---|---|
Gross Profit | $8.8M |
Total Revenue | $27M |
Cost Of Revenue | $18M |
Costof Goods And Services Sold | $18M |
Operating Income | -$184M |
Selling General And Administrative | $51M |
Research And Development | $144M |
Operating Expenses | $196M |
Investment Income Net | - |
Net Interest Income | -$42M |
Interest Income | $21M |
Interest Expense | $64M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $13M |
Income Before Tax | -$237M |
Income Tax Expense | $2.4M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$240M |
Comprehensive Income Net Of Tax | - |
Ebit | -$173M |
Ebitda | -$161M |
Net Income | -$240M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
uniQure NV is a pioneering gene therapy company focused on developing innovative treatments for patients with genetic disorders and other severe diseases. Headquartered in Amsterdam, the Netherlands, uniQure leverages its proprietary AAV-based gene therapy platform to address unmet medical needs, aiming to provide long-lasting solutions for conditions such as hemophilia and neurodegenerative diseases. With a robust pipeline of product candidates and a commitment to transforming patient care through advanced genetic treatments, uniQure is positioned as a leader in the evolving field of gene therapy.